Testing for Increased Lipoproteins (a) [LP(a)] in Lymphedema Patients: Li-LY

NCT05962827 | Recruiting

• 2 other identifiers: 22-AOI-052023-A00407-38
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 2

Brief Summary

Lymphedema is a chronic disease that causes lymph to accumulate in the interstitial tissue. The lymphatic network is involved in the metabolism of lipids and lipoproteins, and this accumulation leads to lipid deposits in the tissues involved. The level of lipoprotein(a) \[LP(a)\] has been shown to be a cardiovascular risk factor, which is partly genetically determined and influenced by certain factors (chronic renal failure, statin treatment, sporting activity or a diet low in saturated fatty acids...). Plasma levels of LP(a) lipoproteins (a) are linearly associated with an increased risk of myocardial infarction and carotid and femoral vascular stenosis. We currently manage patients with primary or secondary lymphedema, whatever the etiology, in the vascular medicine and explorations unit at Nice University Hospital. Those taking part in intensive inpatient decongestive therapy benefit from a blood test, in particular for lipids \[total cholesterol, triglycerides, HDL and LDL cholesterol, apolipoproteins A and B and Lp(a)\]. Our team observed an elevated Lp(a) level \>30 mg/dL in 10 of the 17 patients in whom we carried out this test (whether or not dyslipidemia existed, and whether or not it was known or treated). This is a very high prevalence compared with the general population, in whom an increased level is found in 25% of patients. In view of the impact of Lp(a) on cardiovascular risk and the involvement of the lymphatic system in lipoprotein metabolism, it seems essential to verify our preliminary results on a larger population. In this multicenter cross-sectional trial, we propose to perform Lp(a) lipoprotein assays in lymphedema patients to determine whether there is an increase in this marker in this pathological context. We will also study the concordance of this level with cardiovascular risk assessment scores such as SCORE2/SCORE2-OP and the coronary calcium score. We will look for factors influencing plasma LP(a) levels, both general factors suspected of playing a role and factors specific to lymphedema.

Conditions

Lymphedema

Outcome Measures

Primary Outcomes (1)

• Determine the prevalence of hyperlipoproteinemia (a) in a population of patients with primary or secondary lymphedema

  The primary endpoint will be lipoprotein (a) \> 30 mg/dL, defining hyperlipoproteinemia (a).

  day 0

Secondary Outcomes (2)

• To study the modification of the SCORE-2 /SCORE-OP index of cardiovascular risk assessment at re-evaluation,

  day 5

• To study the modification of the cardiovascular risk assessment calcium score at reassessment, taking into account the presence of hyperlipoproteinemia (a).

  day 5

Study Arms (1)

Determine the prevalence of hyperlipoproteinemia (a) in a population of patients with lymphedema

EXPERIMENTAL

The primary endpoint will be lipoprotein (a) \> 30 mg/dL, defining hyperlipoproteinemia (a).

Diagnostic Test: lipoprotein (a)

Interventions

lipoprotein (a) DIAGNOSTIC_TEST

dosage of lipoprotein (a)

Determine the prevalence of hyperlipoproteinemia (a) in a population of patients with lymphedema

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients over 18 years of age.
• Patient with primary or secondary lymphedema confirmed at consultation or in day hospital.
• Signature of informed consent.
• Person affiliated to or benefiting from a social security scheme

You may not qualify if:

• Person refusing informed consent.
• Pregnant or breast-feeding women (urine pregnancy test performed in women of -childbearing age).
• Patients undergoing secondary cardiovascular prevention (MI, stroke, AOMI, etc.).
• Persons deprived of their liberty by judicial or administrative decision, persons under legal protection.

Sponsors & Collaborators

• Centre Hospitalier Universitaire de Nice: lead

Study Sites (2)

Chu de Nice

Nice, France, 06000, France

RECRUITING

Centre antoine lacassagne

Nice, France, 06003, France

TERMINATED

MeSH Terms

Conditions

Lymphedema

Condition Hierarchy (Ancestors)

Lymphatic Diseases; Hemic and Lymphatic Diseases

Study Officials

• Verena FASSBENDER

  Centre Hospitalier Universitaire de Nice

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Verena FASSBENDER

CONTACT

0492034702; fassbender.v@chu-nice.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 19, 2023
• First Posted: July 27, 2023
• Study Start: December 8, 2023
• Primary Completion (Estimated): August 11, 2026
• Study Completion (Estimated): August 11, 2026
• Last Updated: December 4, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

FR (2)